Deutsche Bank to Provide £1.25 Billion Loan for London's Olympia
The lender will provide £1.25 billion ($1.7 billion) to the venture that has redeveloped the venue, one of the largest real estate financings ever agreed in the UK, a person with knowledge of the process said. The loan will refinance and recapitalizes the business behind the project that's owned by Deutsche Finance International and Yoo Capital, the people said, asking not to be identified as the deal has not yet been signed. JPMorgan Chase & Co. and Evercore arranged the loan, they said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Astera Labs Announces Third Quarter 2025 Financial Conference Participation
SAN JOSE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Astera Labs, Inc. (Nasdaq: ALAB), a leader in semiconductor-based connectivity solutions for rack-scale AI infrastructure, today announced its participation in financial conferences for the third quarter 2025. Deutsche Bank 2025 Technology Conference on Aug. 28, 2025. Astera Labs' presentation is scheduled for 12:30 pm PT. Citi's 2025 Global TMT Conference on Sept. 4, 2025. Astera Labs' presentation is scheduled for 8:50 am ET. A webcast of each session will be made available on Astera Labs' investor relations website at About Astera Labs Astera Labs (NASDAQ: ALAB) provides rack-scale AI infrastructure through purpose-built connectivity solutions grounded in open standards. By collaborating with hyperscalers and ecosystem partners, Astera Labs enables organizations to unlock the full potential of modern AI. Astera Labs' Intelligent Connectivity Platform integrates CXL®, Ethernet, PCIe®, and UALink™ semiconductor-based technologies with the company's COSMOS software suite to unify diverse components into cohesive, flexible systems that deliver end-to-end scale-up, and scale-out connectivity. Discover more at IR CONTACT: Leslie
Yahoo
21 minutes ago
- Yahoo
Mahesh Saptharishi, Executive Vice President and CTO, Motorola Solutions, to Participate in the Deutsche Bank 2025 Technology Conference
CHICAGO, August 20, 2025--(BUSINESS WIRE)--Motorola Solutions (NYSE: MSI), a global leader in public safety and enterprise security, today announced that Mahesh Saptharishi, Executive Vice President and Chief Technology Officer, will participate at the upcoming Deutsche Bank 2025 Technology Conference on Wednesday, August 27, 2025 at 11:45 a.m. PT. A live webcast and replay of the session will be featured on Motorola Solutions' Investor Relations website at About Motorola Solutions | Solving for safer Safety and security are at the heart of everything we do at Motorola Solutions. We build and connect technologies to help protect people, property and places. Our solutions foster the collaboration that's critical for safer communities, safer schools, safer hospitals, safer businesses, and ultimately, safer nations. Learn more about our commitment to innovating for a safer future for us all at View source version on Contacts Investor Contact Tim YocumMotorola +1 847-576-6899 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21 minutes ago
- Yahoo
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
Company announcement – No. 19 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, August 20, 2025 – Zealand Pharma A/S ('Zealand') (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports receipt on 20 August 2025 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder: As of 19 August 2025, Van Herk Investments B.V. (Dutch registration no. 59055057) holds nominally 7,115,191 shares (each share carrying one vote) in Zealand Pharma A/S, corresponding to 9.973% of the total share capital and 9.973% of the total voting rights in Zealand Pharma A/S. Van Herk Investments B.V. is 100% owned by Van Herk Investments THI B.V., which is 100% owned by Van Herk Private Equity Investments B.V. (Dutch registration no. 58894543). Ultimately, Van Herk Private Equity Investments B.V. is owned and controlled by Mr. Adrianus van Herk. Van Herk Management Services B.V. (Dutch registration no. 24377325) controls and exercises the voting rights on behalf of Van Herk Investments B.V., and accordingly, Van Herk Management Services B.V controls and exercises the voting rights on nominally 7,115,191 shares (each share carrying one vote), corresponding to 9.973% of the total share capital and 9.973% of the total voting rights in Zealand Pharma A/S. Van Herk Management Services B.V., is controlled by OGBB A. van Herk B.V. (Dutch registration no. 24160906), which is controlled by A. van Herk Holding B.V. (Dutch registration no. 24160780), which is ultimately controlled by Mr. Adrianus van Herk. Please see further details in the attached notification forms. # # # About Zealand Pharma Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharmaceutical companies as well as commercial partnerships for its marketed was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the United States. For more information about Zealand's business and activities, please visit ContactAdam Lange (Investors) Vice President, Investor Relations alange@ Neshat Ahmadi (Investors) Investor Relations Manager neahmadi@ Anna Krassowska (Investors and Media) Vice President, Investor Relations & Corporate Communications akrassowska@ Attachments 20250819 FSA - Standardformular english Van Herk Investments BV_signed 20250819 FSA - Standardformular english Van Herk Management Services BV_signedError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
